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Phui-Ly Liew1,2, Chih-Yeu Fang2,3, Yu-Chieh Lee4, Yi-Chih Lee5, Chi-Long Chen2,6* and Jan-Show Chu2,6*
Abstract
Background: Increased expression of DEF6 is correlated with the malignant behavior of various cancers. Both DEF6 and
p16 contribute to the regulation of cell cycle progression, and p53 plays important role in the cell cycle checkpoints. This
study was designed to elucidate the prognostic significance of DEF6, p53 and p16 immunoexpressions in different
histology subtypes of ovarian carcinoma.
Methods: Immunohistochemistry results of DEF6, p53 and p16 on ovarian carcinoma were compared with histology
subtypes, clinical data, overall survival (OS) and disease-free survival (DFS) by Cox regression and Kaplan-Meier analysis.
Results: We studied 180 cases of ovarian carcinomas (75 high-grade serous, 41 clear cell, 36 mucinous and 28
endometrioid), including 109 FIGO stage I-II cases and 71 FIGO stage III-IV cases. Ovarian carcinomas positive for both
DEF6 and p16 expression were associated with the worst OS (P = 0.027) and DFS (P = 0.023), whereas those negative for
both DEF6 and p16 had the best OS and DFS. Aberrant p53 expression combined with positive DEF6 was associated with
worst OS (P = 0.031) and DFS (P = 0.028). Kaplan-Meier analysis showed that significantly shorter survival rates were seen
in patients with high expressions of DEF6 (P = 0.008) and p16 (P = 0.022). Patients with aberrant p53 expression in high-
grade serous carcinoma (P = 0.012) and patients with high DEF6 expression in clear cell carcinoma (P = 0.001) were also
associated with shorter overall survival. In univariate analysis, FIGO stage, DEF6 and p16 were associated with poor
prognosis. DEF6 expression was the only independent prognostic factor correlated with shorted OS (HR 2.115; P = 0.025)
and DFS (HR 2.248; P = 0.016) upon multivariate analysis.
Conclusions: DEF6 expression may serve as an independent prognostic factor, and interacted positively with p16 toward
high tumor stage and shorter survival.
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Background
Ovarian carcinoma is the most lethal malignancy of the
female genital tract, mainly due to the failure of early
diagnosis, heterogeneous histology subtypes and the lim-
itations for the conventional chemotherapies [1, 2]. The
important prognostic factors include tumor stage, age at
initial diagnosis, tumor morphological subtypes and
grade, optimal resection for advanced ovarian cancer, as
well as the effect of chemotherapy following primary
surgery [3]. Current researches have focused on the
study of various molecular signaling reactions or path-
ways in ovarian carcinoma to explore the molecular
markers for early detection, prognosis assessment and
hopefully as potential therapeutic targets.
Interferon regulatory factor 4 binding protein (IBP,
also known as: DEF6) first identified in 2003 [4], plays
multiple important roles in various biological processes
that involve the immune system. Loss of DEF6 in mice
resulted in the development of systemic autoimmunity
and developmental defects at the earliest stage of thymo-
cyte differentiation [5–10]. Besides, DEF6 plays import-
ant role in the regulation of cell motility, cytoskeletal
rearrangements, focal complex/adhesion assembly, cell
polarity and cell migration through the stimulation of
actin polymerization [11–17].
Signaling involving DEF6 has been implicated in
tumorigenesis. Increased expression of DEF6 has been
shown to be correlated with the malignant behavior of
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extra-skeletal myxoid chondrosarcoma [18], colorectal
cancer [19], breast cancer cells [20], and oral squamous
cell carcinoma [21]. DEF6 may serve as a potential target
for anti-angiogenic intervention in renal cell carcinoma
[22]. DEF6 is also a novel target of tumor suppressor
p53 and can suppress cisplatin-mediated apoptosis of
breast cancer cells via a negative feedback regulation of
the p53 signaling pathway [23]. High levels of DEF6
were found to decrease cisplatin-induced growth sup-
pression and apoptotic cell death, in association with
decreased p53 activity and imbalanced expressions of
the Bcl-2 family members. Recently, p16 has been shown
as a prognostic indicator in ovarian/fallopian tubal high-
grade serous carcinoma [24–26]. Moreover, both DEF6
and p16 contribute to the regulation of cell cycle pro-
gression, and p53 plays important role in the cell cycle
checkpoints. Despite their potential close interaction in
cell cycle progression, the roles of DEF6, p16 and p53
have not been fully elucidated in ovarian carcinomas.
In the present study, we sought to better understand the
differential expression of DEF6, its relation to the expres-
sions of p53 and p16, and the prognostic significance in
different histology subtypes of ovarian carcinoma based on
a well-defined cohort of ovarian carcinomas. Clinicopatho-
logical data and survival curves were compared between
patients with different scores of DEF6 to explore the poten-
tial of DEF6 as a prognostic marker.
Methods
Patient specimens
We collected cases with surgically operated ovarian car-
cinomas from the files of Departments of Pathology of
Taipei Medical University Hospital and Wan Fang Med-
ical Center between January 1998 and December 2011.
We used the diagnostic criteria of the World Health
Organization classification [1] and tumor staging system
of the International Federation of Gynecology and Ob-
stetrics (FIGO). The pathological diagnosis was reviewed
by at least two pathologists. Cases of secondary metasta-
sis to the ovaries were excluded.
Pathologic variables included histology subtypes (i.e.
low- or high-grade serous carcinoma, mucinous carcin-
oma, endometrioid carcinoma and clear cell carcinoma),
stage, therapy, recurrence free interval (if applicable),
and site of recurrent disease (if applicable). Debulking
surgery was found to be optimal if the maximum diame-
ters of the individual residual tumor deposits were all
less than 1.0 cm. Only cases with optimal resection were
enrolled and analyzed in this study. Patient information
were de-identified and assigned a study number. Tissue
microarrays (TMA) with three to four tumor regions were
chosen from paraffin embedded blocks. Each tumor core
measured 0.3 cm in maximal diameter. This study had
been reviewed and approved by the Institutional Review
Board of Taipei Medical University (TMU-IRB 99049).
Immunohistochemistry and interpretation
The DEF6 monoclonal antibody (clone 1 F2; Abnova,
Taiwan; 1: 3000), p53 (clone: DO-7; Ventena; prediluted),
and p16 (clone: E6H4; Ventena; prediluted) were used.
Formalin-fixed and paraffin-embedded tissue sections were
cut, deparaffinised and rehydrated. Autoclaved retrieval
technique by using 10 mM citric acid buffer (10–20 min)
and inhibited by endogenous peroxidase activity (0.3 %
H2O2; 5 min) were conducted. Tissue sections were incu-
bated with primary antibodies in an automated stainer sys-
tem (Ventana, BenchMark XT). Tissue sections were then
incubated with secondary antibody (dilution rate 1:100,
30 min), peroxidase-conjugated streptavidin (100 μg/mL),
and 0.02 % 3,3’-diaminobenzidine tetrahydrochloride
(DAB) (0.05 M Tris-HCl buffer with 0.03 % H2O2). All
slides were counterstained with hematoxylin and analyzed
by two pathologists (P-L Liew and C-L Chen).
The DEF6 cytoplasmic staining results were scored ac-
cording to the percentages of positive cells: score 0 (less
than 5 %), score 1 (5-24 %), score 2 (25-75 %), and score
3 (more than 75 %). The stromal lymphocytes were
served as positive internal control. The results of p53
and p16 immunostains were scored according to the
percentages of positive cells: score 0 (0 %), score 1 (1-
24 %), score 2 (25-75 %), and score 3 (more than 75 %).
Score 0 and score 3 of p53 were recorded as aberrant
expression; whereas score 1 and score 2 of p53 were des-
ignated as insignificant expression.
Cell lines and cell lysates
Total cell lysates from six ovarian carcinoma cells, in-
cluding A2780, ES-2, TOV-21G, TOV-112D, OVCAR3,
and HBT75, were used for the detection of DEF6 ex-
pression by Western blotting. A2780 (ovarian carcin-
oma cell line with unknown disease type identification)
cell was cultured in RPMI-1640 with 10 % fetal bovine
serum (FBS). ES-2 (clear cell carcinoma), TOV-21G
(clear cell carcinoma) and TOV-112D (endometrioid
carcinoma) were obtained from ATCC bioresource cen-
ter (Manassas, VA, USA). ES-2 was cultured in McCoy’s
5 medium with 10 % FBS. TOV-21G and TOV-112D
were cultured in a 50:50 mixture of Medium 199 and
MCDB105 with 10 % FBS. Cells were grown to near
confluent, washed with PBS, and then lysed by RIPA
lysis buffer. The lysates of OVCAR3 (serous carcinoma)
and HBT75 (serous carcinoma) cells were kindly pro-
vided by Prof. Chao-Lien Liu at the Department of
Medical Laboratory Science and Biotechnology, Taipei
Medical University.
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Western blot assay
Lysates from the six ovarian carcinoma cell lines and
two positive control oral carcinoma cells, HSC-3 and
SCC25, were separated in a 10 % polyacrylamide gel and
transferred onto a PVDF membrane. After blocking, the
blot was incubated with indicated antibodies overnight at
4 °C. Antibodies against DEF6and β-actin (Genetex, Irvine,
CA, USA) were used as the primary antibodies. After wash-
ing, the blot was incubated with horseradish peroxidase-
labeled goat anti-mouse/rabbit IgG (Jackson Laboratory).
The expression profile of the proteins was visualized using
a Western Lightening-ECL kit (PerkinElmer, Waltham,
MA, USA).
Statistical analyses
We performed statistical analyses by using SPSS for
Windows software (SPSS, Chicago, IL). Data were
expressed as median (interquartile range), mean (SD),
and percentages. Chi-square test, Mann-Whitney U
tests, and Student’s t-test were used as statistical
methods. Spearman rank correlation and multivariate
linear regressions with stepwise variable selection were
performed to assess the significant associations between
ordinal or continuous predictor variables. The Kaplan-
Meier method, Cox proportional hazard regression
model and multifactorial Cox regression analysis were
used to examine all factors found to be prognostic of
survival in univariate analysis and the analysis of DFS
and OS. A P-value of less than 0.05 was considered sta-
tistically significance.
Results
Comparison of DEF6, p53 and p16 expressions in different
histological subtypes
In our cohort of study, we collected 180 cases of ovarian
carcinomas (75 high-grade serous, 41 clear cell, 36
mucinous, and 28 endometrioid carcinomas). We did
not enroll cases of low-grade serous carcinoma because
only three cases of low-grade serous carcinoma were
diagnosed. The patients’ ages ranged from 25 to 93 years
(mean: 53.8 years). Totally 109 early stage cases (FIGO
stage I-II) and 71 advanced stage (FIGO stage III-IV),
with a median follow-up time of 33.0 months (mean,
48.3 months; range, 1 to 146 months) were enrolled.
The surgical procedures included total hysterectomy, bi-
lateral salpingo-oophorectomy, pelvic and/or para-aortic
lymph nodes sampling and omentectomy.
As shown in Table 1, immunoexpressions of DEF6,
p53 and p16 showed significant correlation with differ-
ent histological subtypes of ovarian carcinoma. Score 3
immunoexpression of DEF6 could be assessed in 52 %
(39/75) and 64.3 % (18/28) of high-grade serous carcin-
oma (Figs. 1a, b, c and d) and endometrioid carcinoma,
respectively. Aberrant p53 expression was also observed
in 82.7 % of high-grade serous carcinoma. The p16
expression was either cytoplasmic or showed a combin-
ation of nuclear and cytoplasmic immunoreactivity. The
Table 1 Correlation of DEF6, p53 and p16 expression in histological subtypes of ovarian carcinoma
Histology subtypes of ovarian carcinoma
Serous carcinoma (N = 75) Mucinous carcinoma (N = 36) Endometrioid carcinoma (N = 28) Clear cell carcinoma (N = 41)
Antibody Score No. (%) No. (%) No. (%) No. (%) P-value
DEF6 0 8 (10.7) 8 (22.2) 2 (7.1) 6 (14.6) <0.001*
1 7 (9.3) 12 (33.3) 4 (14.3) 15 (36.6)
2 21 (28.0) 9 (25.0) 4 (14.3) 11 (26.8)
3 39 (52.0) 7 (19.4) 18 (64.3) 9 (22.0)
NA 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
p53 0 26 (34.7) 12 (33.3) 6 (21.4) 6 (14.6) <0.001*
1 11 (14.7) 17 (47.2) 18 (64.3) 29 (70.7)
2 1 (1.3) 2 (5.6) 1 (3.6) 2 (4.9)
3 36 (48.0) 5 (13.9) 3 (10.7) 4 (9.8)
NA 1 (1.3) 0 (0.0) 0 (0.0) 0 (0.0)
p16 0 12 (16.0) 29 (80.6) 11 (39.3) 14 (34.1) <0.001*
1 6 (8.0) 3 (8.3) 6 (21.4) 16 (39.0)
2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
3 56 (74.7) 3 (8.3) 11 (39.3) 10 (24.4)
NA 1 (1.3) 1 (2.8) 0 (0.0) 1 (2.4)
NA, Not applicable (not enough material for analysis or technical limitations)
P- value Fisher’s exact or Chi-square test analysis (*significant difference)
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expression of p16 could be observed in 74.7 % (56/75) of
high-grade serous carcinomas, and commonly lost (up
to 80.6 %) in mucinous carcinomas. There was some
variation in p16 staining in the endometrioid carcinoma
and clear cell carcinoma groups. In summary, high-
grade serous carcinoma showed the highest frequencies
of increased DEF6 and p16 expressions, as well as aber-
rant p53 expression.
Expression of DEF6 in ovarian carcinoma cell lines
The expression profile of DEF6 was studied in several
ovarian carcinoma cell lines by Western blot. Among six
ovarian carcinoma cells examined, the expression of DEF6
in TOV-112D (endometrioid carcinoma) and OVCAR3
(serous carcinoma) cells were found to be relatively high
when compared to other ovarian cells (Fig. 2). These
findings were compatible with immunohistochemical re-
sults. This indicated that DEF6 was preferentially overex-
pressed in ovarian serous and endometrioid carcinomas.
The level of DEF6 in A2780 (unknown histology subtype)
and TOV-21G (clear cell carcinoma) was comparatively
low among the six cells, however, they revealed a double-
band pattern on the DEF6 region as similar to the oral
carcinoma cells.
Prognostic values of co-expression DEF6/p16 and DEF6/p53
We analyzed the prognostic significance of DEF6, p16
and p53 in the whole group of 180 cases of ovarian car-
cinoma. Four subgroups of patients each were formed
according to DEF6/p16 and DEF6/p53 co-expressions
(Table 2). The group with positive DEF6 and positive p16
expression was associated with the lowest OS (P = 0.027)
Fig. 1 Cytoplasmic immunoexpression of DEF6 in high-grade serous carcinoma. Case representatives show (a) negative (less than 5 %): score 0;
(b) weak (5–25 %): score 1; (c) moderate (26–75 %): score 2; (d) strong (more than 75 %): score 3 of tumor cells
Fig. 2 Expression of DEF6 in ovarian carcinoma cell lines. The expression profile of DEF6 was studied in six ovarian carcinoma cell lines. A2780: unknown
type; ES-2 and TOV-21G: clear cell carcinoma; TOV-112D: endometrioid carcinoma; OVCAR3 and HBT75: serous carcinoma. Two oral carcinoma cells, HSC-3
and SCC25, were included as positive controls. β-actin is detected as a loading control
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and DFS (P = 0.023), whereas the DEF6 and p16 negative
group had the highest OS and DFS. Similarly, the presence
of aberrant p53 expression with concomitant DEF6 expres-
sion was statistically associated with worst prognosis,
whereas the group negative for both had the best OS and
DFS (P = 0.031 for OS and P = 0.028 for DFS, respectively).
Effects of DEF6, p16 and p53 expression on the patient’s
overall survivals
Ovarian carcinoma patients with high DEF6 expression
were associated with a poor overall survival compared with
the patients with low DEF6 expression (P = 0.008; Fig. 3a).
Also, ovarian carcinoma patients with high 16 expression
had lower overall survival rate than those with low p16
expression, as determined using the Kaplan-Meier method
(P = 0.022; Fig. 3b). Subsequently, we carried out survival
analyses according to IHC evaluations in four different
histological subtypes of ovarian carcinoma (see Additional
file 1). Patients with aberrant p53 expression had shorter
survival rate than those with insignificant p53 expression in
high-grade serous carcinoma (P = 0.012). More importantly,
in ovarian clear cell carcinoma, high expression of DEF6
was associated with shorter overall survival as compared to
low DEF6 expression (P = 0.001, Fig. 4).
Prognostic effects of clinicopathological factors and
immunohistochemistry
Univariate (Table 3) and multivariate (Table 4) analyses
were conducted to analyze the clinicopathological and
IHC characteristics of the ovarian cancer patient cohorts to
elucidate the crucial prognostic factors. Univariate analysis
identified FIGO stage (P = 0.023 for OS and P = 0.034 for
DFS), DEF6 (P = 0.013 for OS and P = 0.009 for DFS) and
p16 (P = 0.026 for OS and P = 0.031 for DFS) as prognostic
factors. Upon multivariate analysis, strong DEF6 was the
only independent prognostic factor correlated with shorted
OS (HR 2.115; P = 0.025) and DFS (HR 2.248; P = 0.016).
Discussion
DEF6 is a conserved protein associated with the func-
tions of lymphocytes and is highly expressed in T-cells
and T-cell homing organs [4–27]. DEF6 was expressed
in breast cancer cells [20], oral squamous cell carcinoma
[21], colorectal carcinoma [19], and in tumor vessels of
renal cell carcinoma [22]. The role of DEF6 expression
in human cancer is unclear, and the prognostic signifi-
cance of DEF6 expression and the co-expression of p16
and p53 in ovarian carcinomas are largely unknown.
In this study of 180 cases of ovarian carcinoma using
immunohistochemistry, a high expression of DEF6 was
commonly found in ovarian carcinomas, and associated
with different histology subtypes, advanced FIGO stage,
and reduced overall survival (OS) and disease free
survival (DFS). Strong expression of DEF6 was observed
in high-grade serous carcinoma and endometrioid car-
cinoma. These findings were supported by the high ex-
pression of DEF6 in two serous, two clear cell and one
endometrioid carcinoma cell lines, suggestive of the
Table 2 Overall survival (OS) and disease-free survival (DFS) according to DEF6/p16 and DEF6/p53 co-expressions




75 (11) 53–98 90 (30)
30–149





54 (16) 22–86 48 (30)
0–107




41 (10) 22–61 27 (10)
6–47




32 (6) 19–45 21 (4)
12–30




/p53 (scores 1 and 2)
73 (10) 52-93 72 (20)
31-113




/p53 (scores 0 and 3)
64 (17) 30–99 76 (79)
0–230
64 (17) 30–97 76 (79)
0–230
DEF6-postive
/p53 (scores 1 and 2)
48 (11) 26–70 48 (25)
0–97
44 (10) 22–65 31 (16)
0–62
DEF6-positive
/p53 (scores 0 and 3)
29 (6) 16–41 19 (2)
13–24
28 (6) 16–41 17 (1)
14–19
SE, Standard error; CI, confidence interval
*significant difference
Log-rank test
DEF6 positive: Scores 2 and 3; DEF6 negative: Scores 0 and 1
p16 positive: Scores 2 and 3; p16 negative: Scores 0 and 1
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Fig. 3 Kaplan-Meier curves for overall survival according to protein expression levels in ovarian carcinomas (n= 180). a Patients with high DEF6 expression
(scores 2 and 3; n= 118) versus low DEF6 expression (scores 0 and 1; n= 62). (H: high DEF6 expression; L: low DEF6 expression); (b) Patients with high p16
expression (scores 2 and 3; n= 80) versus low p16 expression (scores 0 and 1; n= 97). (H: high p16 expression; L: low p16 expression)
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frequent expression of DEF6 in ovarian carcinoma tis-
sues and cells.
There are many molecular markers possessing prog-
nostic value. We compared the clinicopathological
parameters and prognostic factors of DEF6, p16 and
p53. The p16 is a cyclin-dependent kinase inhibitor
which is integral to the retinoblastoma (Rb) gene-
mediated control of the G1-S phase transition of the cell
cycle [28]. It was also shown that ectopic expression of
DEF6 shortened the G1 interval in the cell cycle, and in-
creased cyclin D1 expression [21]. It is therefore import-
ant to explore the cooperation between the two genes in
the tumor progression. Although p16 has been widely
regarded as a surrogate marker of high-risk human pap-
illomavirus (HPV) in uterine cervical pathology, the role
of p16 protein expression in ovarian carcinomas remains
limited. In our study (Table 1), we found the highest per-
centage of score 3 p16 expression (74.7 %) in high-grade
serous carcinoma, an ovarian carcinoma with notorious
poor outcome, and similarly DEF6 (52 %). Our findings
suggest that p16 is also a valuable prognostic marker for
ovarian carcinomas. Recent studies have investigated the
diagnostic role of p16 and prognostic indicator of p16
with clinical outcome in ovarian/tubal high-grade serous
carcinoma. As p16 was expressed in the majority of p53-
positive and p53-negative serous tubal intraepithelial
carcinomas, the addition of p16 helped to compensate
the practical limitations of p53 in the diagnosis of serous
tubal intraepithelial carcinomas [24]. Moreover, a recent
study on ovarian/tubal high grade serous carcinomas
revealed three distinct subgroups according to p16 ex-
pression and RB1 status (i.e., p16 homogenous stain/RB1-
, p16 homogenous stain/RB1+, and p16 heterogeneous
stain/RB1+), which possessed clinical relevance for stage
and patient outcome upon multivariate analysis [29]. We
also assessed the prognostic significance of the status of
DEF6/p16 co-expression. Notably, the co-expression of
both proteins was associated closely with adverse clinical
outcome (Table 2). The OS and DFS, in particular, were
the shortest in the group with strong DEF6 and p16 co-
expression, followed by DEF6+/p16- and DEF6-/p16+,
while the DEF6-/p16- group had the longest survival rates
(P = 0.027 for OS and P = 0.023 for DFS, respectively).
These findings suggest that DEF6 and p16 positively inter-
act and contribute to the tumor progression in ovarian
carcinoma, and the molecular mechanisms deserve to be
further studied. This suggestion is supported by the obser-
vations that both proteins play important role in the con-
trol of the G1-S phase transition of the cell cycle [21, 28].
DEF6 is a novel p53 target gene and negatively regu-
lated by p53, it can suppress cisplatin-mediated apop-
tosis of breast cancer cells [23]. In the present study, we
Fig. 4 Kaplan-Meier curves for overall survival in patients with high DEF6 expression (scores 2 and 3; n = 21) versus low DEF6 expression (scores 0 and
1; n = 20) in clear cell carcinoma. (H: high DEF6 expression; L: low DEF6 expression)
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Table 3 Univariate analyses showing HRs for patient OS and DFS conferred age, FIGO stage, histologic subtypes, DEF6, p53, p16 and
ER expression (N = 180)
Variables Total
No.
Overall survival (OS) Disease-free survival (DFS)
HR 95 % CI P -value HR 95 % CI P -value
Age, years 0.990 0.900
≦50 72 1.00a 1.00a
>50 108 1.003 0.595–1.693 1.034 0.613–1.745
FIGO stage 0.023* 0.034*
I 86 1.00a 1.00a
II 23 1.141 0.518–2.511 1.119 0.509–2.460
III 64 2.282 1.217–4.279 2.166 1.161–4.040
IV 7 5.300 1.173–23.950 4.939 1.100–22.172
Histologic subtypes 0.303 0.284
Serous carcinoma 75 1.00a 1.00a
Mucinous carcinoma 36 0.529 0.247–1.135 0.531 0.247–1.138
Endometrioid carcinoma 28 0.786 0.342–1.808 0.882 0.382–2.037
Clear cell carcinoma 41 0.607 0.317–1.162 0.608 0.318–1.163
DEF6 0.013* 0.009*
Scores 0 and 1 62 1.00a 1.00a
Scores 2 and 3 118 2.041 1.159–3.594 2.119 1.202–3.737
p16 0.026* 0.031*
Scores 0 and 1 97 1.00a 1.00a
Scores 2 and 3 80 1.919 1.082–3.402 1.873 1.057–3.318
p53 0.181 0.205
Scores 1 and 2 81 1.00a 1.00a
Scores 0 and 3 98 1.450 0.841–2.499 1.421 0.825–2.448
aReference category for HR (Hazard Ratio) calculation with variable
CI: Confidence Interval. (*Significant difference)
Table 4 Multivariate analyses showing HRs for patient OS and DFS conferred FIGO stage, DEF6 and p16 expression (N = 180)
Variable Overall survival (OS) Disease-free survival (DFS)
HR 95 % CI P -value HR 95 % CI P -value
FIGO stage
I 1.00a 1.00a
II 0.624 0.235–1.658 0.344 0.591 0.222–1.575 0.293
III 1.480 0.563–3.890 0.426 1.373 0.522–3.609 0.520
IV 3.845 0.734–20.133 0.111 3.496 0.671–18.206 0.137
DEF6 0.025* 0.016*
Score 0 and 1 1.00a 1.00a
Score 2 and 3 2.115 1.097–4.079 2.248 1.161–4.352
p16 0.611 0.611
Score 0, 1 and 2 1.00a 1.00a
Score 3 1.250 0.530–2.945 1.250 0.529–2.953
aReference category for HR (Hazard Ratio) calculation with variable
CI: Confidence Interval. (*Significant difference)
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found that strong DEF6 expression and aberrant p53
expression had the shortest survival, whereas co-
expression of insignificant p53 expression and negative
DEF6 displayed the longest survival rate, with the other
two groups in between (P = 0.031 for OS and P = 0.028
for DFS, Table 3). Thus, the evaluation of the p53 status
coupled with DEF6 might be important for risk stratifi-
cation, which certainly awaits sequencing validation of
the p53 status for further clarification.
We further evaluated the overall survival rates of DEF6,
p16 and p53 in all patients and four different histology
subtypes of ovarian carcinoma by using Kaplan-Meier
analysis. Significantly shorter survival rates were seen in
patients with high expressions of DEF6 (P = 0.008) and
p16 (P = 0.022). Patients with aberrant p53 expression in
high-grade serous carcinoma had shorter overall survival
(P = 0.012). Surprisingly, high expression of DEF6 in clear
cell carcinoma was significantly correlated to shorter over-
all survival (P = 0.001). We enrolled in total 41 cases of
ovarian clear cell carcinoma (30 FIGO stage I, 4 FIGO
stage II and 7 FIGO stage III) in this study. Therefore, our
study suggests that patients of ovarian clear cell carcinoma
with high DEF6 expression deserve a poor prognostic fac-
tor compared with other histological subtypes. Our study
is the first report on the prognostic impact of DEF6 over-
expression in early-stage ovarian clear cell carcinomas,
however in-depth investigations are necessary.
Univariate analysis showed that FIGO stage, DEF6 and
p16 were associated with shorter survival (Table 3). Upon
multivariate analysis, DEF6 remained the significant prog-
nostic value (Table 4). These findings suggest that DEF6
in ovarian carcinomas may facilitate tumor cell growth or
proliferation, motility, invasion and metastasis, leading to
high tumor stage and hence poor prognosis.
Conclusions
DEF6 was often overexpressed in ovarian carcinomas, par-
ticularly in high-grade serous carcinoma and endome-
trioid carcinoma cells and tissues. DEF6 overexpression in
early-stage ovarian clear cell carcinomas may have poten-
tial role as a poor prognostic factor. Multivariate analysis
showed that DEF6 might serve as independent prognostic
biomarker. Our findings suggest that DEF6 contribute
cooperatively with p16 and p53, another two important
cell cycle regulators, toward high tumor stage and poor
OS and DFS in ovarian carcinomas. Hence DEF6 expres-
sion deserves further investigation especially its potential
as therapeutic target in the dreadful ovarian carcinomas.
Additional file
Additional file 1: Figure S1. Kaplan-Meier curves for overall survival in
four histological subtypes of ovarian carcinoma patients according to DEF6,
p16 and p53 expressions. A, Patients with high DEF6 expression (scores 2
and 3; n = 60) versus low DEF6 expression (scores 0 and 1; n = 15) in high-
grade serous carcinoma. (H: high DEF6 expression; L: low DEF6 expression).
B, Patients with high p16 expression (scores 2 and 3; n = 56) versus low p16
expression (scores 0 and 1; n = 18) in high-grade serous carcinoma. (H: high
p16 expression; L: low p16 expression). C, Patients with aberrant p53 expres-
sion (scores 0 and 3; n = 62) versus insignificant p53 expression (scores 1
and 2; n = 12) in high-grade serous carcinoma. D, Patients with high DEF6
expression (scores 2 and 3; n = 20) versus low DEF6 expression (scores 0 and
1; n = 16) in mucinous carcinoma. (H: high DEF6 expression; L: low DEF6
expression). E, Patients with high p16 expression (scores 2 and 3; n = 32)
versus low p16 expression (scores 0 and 1; n = 3) in mucinous carcinoma.
(H: high p16 expression; L: low p16 expression). F, Patients with aberrant
p53 expression (scores 0 and 3; n = 17) versus insignificant p53 expression
(scores 1 and 2; n = 19) in mucinous carcinoma. G, Patients with high DEF6
expression (scores 2 and 3; n = 6) versus low DEF6 expression (scores 0 and
1; n = 22) in endometrioid carcinoma. (H: high DEF6 expression; L: low DEF6
expression). H, Patients with high p16 expression (scores 2 and 3; n = 17)
versus low p16 expression (scores 0 and 1; n = 11) in endometrioid
carcinoma. (H: high p16 expression; L: low p16 expression). I, Patients with
aberrant p53 expression (scores 0 and 3; n = 9) versus insignificant p53
expression (scores 1 and 2; n = 19) in endometrioid carcinoma. J, Patients
with high p16 expression (scores 2 and 3; n = 30) versus low p16 expression
(scores 0 and 1; n = 11) in clear cell carcinoma. (H: high p16 expression; L:
low p16 expression). K, Patients with aberrant p53 expression (scores 0 and
3; n = 10) versus insignificant p53 expression (scores 1 and 2; n = 31) in clear
cell carcinoma. (ZIP 195 kb)
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